An Open-Label Pilot Study for Atomoxetine in Adult Subjects With Attention Deficit/Hyperactivity Disorder.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 03 May 2008 Status changed from in progress to completed.
- 08 Mar 2008 Status changed from recruiting to in progress.
- 04 Oct 2007 New trial record.